USPTO issues Notice of Allowance to Neurana Pharmaceuticals for two new tolperisone patents

US Patent and Trade Office (USPTO) has issued Notice of Allowance to Neurana Pharmaceuticals for two new tolperisone patents, including a second Composition of Matter patent for a novel form of tolperisone. The company also received a Notice of Allowance for a Method of Making patent.

Tolperisone, an approved product that has regulatory approval and is commercialized in many countries outside the United States, has demonstrated improvement in the treatment of skeletal muscle disorders without sedation.  A requirement by the US FDA for a highly purified form of tolperisone provided the basis for the four patents that are either issued or subject to issuance. The tolperisone patent family term extends to 2032. Tolperisone also was granted a composition of matter patent that has been issued in Canada.

Neurana is the exclusive licensee for tolperisone in North America and other territories from Sanochemia Pharmazeutika AG (ISIN: AT0000776307).  The licensing agreement provides Neurana the right to develop and market Sanochemia’s proprietary and patent protected tolperisone formulation in the United States and other licensed territories. Neurana plans to initially develop tolperisone for the treatment of acute, painful muscle spasms as well as for spasticity.